"Through this strategic acquisition we are excited to expand our European footprint – building our presence in the French market. This addition to our portfolio of CNS medicines underscores our commitment to improving the lives of patients suffering from psychiatric and neurological disorders. We are eager to leverage our expertise and resources to maximise the potential of these therapies."
Ben Moore, Vice President of Corporate Development
"It has been pleasure to work with the CNX team, supporting another successful acquisition. This is a great opportunity for CNX to expand their European operations, and continue to improve the lives of patients. We look forward to continuing to work with the team in the future!"
Lewis Winston, Director, BDO LLP
The BDO project team included Andrew Howson, Lewis Winston, Amy Banister and Issie Thomas.